Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Metabolife 356

This article was originally published in The Tan Sheet

Executive Summary

Randomized, placebo-controlled, dual-arm study of 67 people published in March International Journal of Obesity shows ma huang/guarana combination supplement is efficacious with minimal side effects. Active arm, which took 72 mg ephedrine alkaloids and 240 mg caffeine daily for eight weeks, averaged a 4 kg weight reduction and a 3.5% body fat loss. Led by Carol Boozer, Columbia University, et al., the trial indicates further study on long-term use of the product is warranted, researchers say. Boozer, along with Patricia Daly, MD, also authored a study using ma huang/kola nut that was part of the recent Cantox Health Sciences report commissioned by CRN (1"The Tan Sheet" Jan 1, pp. 3-4)

You may also be interested in...



Ephedra/AER Causality Link Not Possible - Cantox/CRN

Ephedrine alkaloid adverse event reports recorded in FDA's Special Nutritional Adverse Event Monitoring System do not establish causation between supplements containing the popular weight loss and sports herbal ingredient and reported AEs, according to a report commissioned by the Council for Responsible Nutrition.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel